/Investor DB

Andera Partners

Private equityoperating company · company profile

Paris · Seed–Growth · 131 people tracked

Also known as Andera

Find your way into Andera Partners

Sign up to see every warm intro you have to Andera Partners

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Andera Partners team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

✨ Fox Verdict
Sign up to see your fit

Investment thesis

Andera Partners is a private equity asset manager that helps companies innovate, grow and adapt to changing environments. Central to its approach is the belief that strong partnership between investors and entrepreneurs is essential to sustainable development, captured in its 'Power of And' signature. The firm draws on expertise across multiple areas to offer well-defined investment strategies and bespoke solutions tailored to the challenges faced by business leaders and their models.

Source: firm website, verified Oct 13, 2026.

Stage
Seed–Growth
HQ
Paris, FR
Instruments
Equity
Founded
2004
Last 12 months
4 investments
AUM
$6B
VC funds
4
Tracked investments
303
Unicorns
1
IPOs
4
Acquisitions
8

Team · 131 people

from the firm's website & curated & public directories
Aneta Sottil· Partnerin
Antoine Le Bourgeois· Partnerin
David Robin· Partner in charge of Andera Expansion activitiesin

Partner leading the Andera Expansion team and overseeing the fund's investment strategy in growth LBOs and buy-and-build operations across niche industries and B2B services.

Jan Van den Bossche· Partnerin
Laurent Tourtois· Partnerin

Laurent Tourtois is a Partner at Andera Partners focused on private equity investments in the French and Belgian mid-market. His experience spans fund raising, deal origination, valuation, corporate finance, strategy, due diligence, and mergers and acquisitions.

Léopold Brichard· Partnerin

Léopold Brichard is a Partner at Andera Partners with background in audit and corporate finance. He previously worked at Ernst & Young's Transaction Services department conducting financial due diligence on mergers, acquisitions, and divestitures for private equity and corporate clients, and held a Senior Associate position at EDRIP beginning in 2016. He is a graduate of HEC School of Management.

Mayeul Caron· Partnerin
Olivier Le Gall· Partnerin

Olivier Le Gall is a partner at Andera Partners focused on private equity investments in consumer, healthcare, business services, and TMT sectors. He takes both majority and minority stakes in small and medium-sized enterprises, with a portfolio including companies across IT services, healthcare, construction, beverages, real estate technology, fashion, and food production in France and northern Europe. He serves as non-executive chairman of ElaN Languages.

Olivier Litzka· Partnerin
Raphaël Wisniewski· Partnerin
Sofia Ioannidou· Partnerin
Sylvain Charignon· Partnerin

Sylvain Charignon is a Partner at Andera Partners with experience in the financial services industry. His professional background includes expertise in leveraged buyouts, corporate finance, corporate development, growth capital, and private equity.

François-Xavier Mauron· Partnerin

Francois Xavier Mauron is a Partner at Andera Partners with experience in the investment management industry. His expertise spans LBO, valuation, corporate finance, due diligence, and mergers & acquisitions. He holds an MBA in Corporate Finance from HEC.

Antoine Guérillon· Investment Directorin

Antoine Guérillon is an Investment Director at Andera Partners, where he works with the Andera Acto division focused on non-dilutive financing solutions for entrepreneurs and management teams. The division structures flexible capital arrangements including mezzanine debt, preferred stock, and common equity, and typically deploys €20 million to €100 million per transaction while providing strategic and operational support to portfolio companies.

Camille Coll· Investment Directorin
Elyes Chouaieb· Investment Directorin
Florian Gerard-Mercier· Investment Directorin𝕏

Florian Gerard-Mercier is an Investment Director at Andera Partners' Life Sciences team in Paris, where he has worked since April 2021. He holds a background in brain science research and brings expertise in mathematics, physics, and computer science to his venture capital work in biotech and medtech. Gerard-Mercier co-founded and directed studies at le Millénaire, a public policy think tank focused on health, innovation, and industrial policy, and has spent six years working internationally in Tokyo.

Hanna Tayeb· Investment Directorin
Julia Joannot· Senior Investment Managerin

Julia Joannot is a Senior Investment Manager at Andera Partners with experience in private equity transactions spanning growth deals and industrial real assets. She has executed cross-border transactions across France, Brazil, and the United States, and maintains proficiency in French, English, Portuguese, and Spanish. Her investment focus includes renewable energy production, sustainable food systems, decarbonized mobility, and green data centers.

Mathieu Piéronne· Directorin
Nicolas Debonneuil· Investment Directorin
Yuexin Yu· Directorin
Loan Hoang-Sayag· Venture Partnerin

Dr. Loan Hoang-Sayag serves as Venture Partner at Andera Partners. Board-certified in hematology and medical oncology, she has twenty-five years of clinical development experience in hematology and oncology across academic, pharmaceutical, biotechnology, and CRO settings.

Thierry Hercend· Venture Partner
Julie Pinto de Oliveira· Senior Manager
Kenza Rguyeg· Sales Support
Nina Ulmer· Graphic Design and Communication Assistant
Phyléas Huneau· Compliance and Internal Control Assistant
Sandy Blin· Senior Investment Manager
Achille Robert· Senior Manager
Alban Ravinet· Senior Investment Manager
Albane Richard· Investment Manager
Alexander Cuniasse· Partner
Alice Bacquet· Senior Manager
Alvaro Canosa· Investment Manager
Andrei Buzdugan· CFO
Anissa Peer· Investment Manager
Anne-Claire Picchiottino· Investment Director
Anne-Laure Delavergne· Middle-Office Manager

Anne-Laure Delavergne joined Andera Partners in January 2021 as a middle-office manager within the Andera MidCap and Andera Expansion teams. She previously worked at Capintech, TechFund Europe Management (from 2004) as back and middle-office manager, and Demeter Partners (from 2009), where she handled investor reporting and fund middle-office. She holds a Master 2 in Technology and Innovation Management from Paris IX Dauphine University.

Antoine Soucaze· Director
Armelle Okoye· Middle Office
Arnaud Faure· Partnerin
Augustin Bayvet· Senior Investment Managerin
Aurélie Owona· Director
Bruno Angles· Strategic Advisorin

Bruno Angles is President of the Fondation des Bernardins since September 2025 and President of Polytechnique Insights since February 2025, while also serving as Senior Advisor at Oliver Wyman and Strategic Advisor at Andera Partners. A graduate of the École Polytechnique and the Collège des Ingénieurs and an engineer of the corps des Ponts et Chaussées, he served as Directeur général of AG2R LA MONDIALE from May 2022 to January 2025 and as President France and Belgium of Credit Suisse from April 2016 to April 2021, following earlier roles at Autoroutes et Tunnel du Mont-Blanc, McKinsey, Vinci Énergies, Mercer Delta, and Macquarie. He currently serves as an administrator of the Fondation de France and previously led the Association des anciens élèves et diplômés de l'École polytechnique.

Bruno Bonnin· Partner
Camille Leloup· Middle Officer
Carlo Cartapani· Investment Director
Cécile Ah-Fa· Senior Investment Manager
Cécile-Laure Fansi· Middle Office
César Bernand· Investment Manager
Charles Guion de Méritens· Senior Investment Manager
Charlotte Phelippeau· HR Manager
Christophe Leroy· Director
Claire Merat Balaïan· Middle Officer
Clarisse Perrier· Analyst
Clément Legendre· Manager
Coralie Dabiens· Sustainability Manager
Domitille de Vienne· Director
Elisabeth Mazières· Accountant
Elisabeth Penda· Executive Assistant
Eloïse Arriberouge· Communication and Events Officer
Elsa Baillet· Sustainability Manager
Emmanuelle Payet· Middle Office
Enrico Papi· Investment Manager
Etienne Rossignol· Investment Directorin
Filippo Alberti· Senior Manager
Flavien Laboudigue· Senior Financial Controller
Francesco Gonzaga· Partnerin
Gladys Grolier· Legal Advisor
Gonzalo Boada· Director
Gregory Mengus· Assistant Accounting Manager
Guillaume Thomas· Director
Guy Auger· Partnerin
Hans J. Moebius· Venture Advisorin

Hans J. Moebius is a Venture Advisor at Andera Partners, focusing on central nervous system drug development. He holds a B.S. in Chemistry, a medical degree, and a PhD in Experimental Pharmacology, and is a board-certified neurologist (FAAN) and psychiatrist with a European Certificate in Pharmaceutical Medicine. His career spans over a decade of clinical work in university settings and more than 30 years in the pharmaceutical industry, including a role as Chief Medical Officer during Athira's 2020 IPO and involvement in the development of therapies for conditions such as Alzheimer's disease, hepatic encephalopathy, Lennox-Gastaut syndrome, and ADHD.

Hans Van de Velde· Senior Advisor – Belgiumin

Hans Van de Velde joined Andera Partners as Senior Advisor for Belgium to develop investment opportunities in the country alongside the WINCH Capital and CABESTAN Capital teams. He previously worked as a partner at AAC Capital covering the Belgian market with a focus on mid-sized growth companies, and held roles at Deloitte's CF Advisory practice and at ABN Amro Bank. He holds an MSc in Business Engineering from the University of Leuven in Belgium.

Hawa Dème-Kuwan· Chief Compliance Officer
Henri Elbaz· Director
Ignacio Moreno Martinez· Senior Advisor Spain
Ines Da Silva· HR Officer
Jean-Baptiste Bessières· Partner
Jeanne Chabenat· Chargée d'Affairesin

Jeanne Chabenat joined Andera Partners in November 2024 as an Analyst on the Andera Expansion team and now works as a Chargée d'Affaires. She previously worked at the investment fund MBO+. She holds a Master's in Corporate Finance and Financial Engineering from Université Paris-Dauphine.

Joaquìn Gonzalo· Senior Advisor Spainin
Juan-Camilo Galindo· Cybersecurity Analyst
Katia von Borowski· Investment Director
Laetitia Guetta· Head of HR
Laura Gauffre· Senior Financial Controller
Laurent Fichter· Partnerin
Loïc Guyomard· Financial Controller
Lou Bessonneau· IT Support
Louis Hamon· Partner
Louis Vazeux· Analyst
Louise Le Guen· Sustainability Analyst
Lounès Moumou· Analyst
Luc Beaupoux· IT Manager
Manon Valaize· Analyst
Maria Arce Avila· General Services Officer
Mathis Merlot· Investment Manager
Maurizio Bottinelli· Senior Advisor Italy
Maxime Sabourin· Senior Manager
Mickael Clavier· Chief Digital & Data Officer
Natali Romero Barrios· Senior Investment Managerin

Natali Romero Barrios is a Senior Investment Manager at Andera Partners, focused on venture capital in the healthcare sector. She holds a Ph.D. in Biology from the Université Paris-Saclay and a Specialized Master's in Pharmaceutical and Biotechnology Management from ESCP.

Nicolas Aftimos· Directorin𝕏
Nicolas Delsert· Chief Communication Officer
Noëlla De Bermingham· Chief Sustainability Officer
Philippine Gallot· Investment Manager
Pierre Barruet· Director of Financial Control
Pierre Flin· Investment Managerin
Pierre Millot· Director
Pierre-Yves Poirier· Partnerin
Prune Des Roches· Partner
Raphaël Elbaz· Analyst
Raymond W. Cohen· Venture Advisorin

Operating Partner and multi-exit CEO/Chairman.

Romain Lagrange· Communications Manager
Romane Ponce· Compliance Officer
Sabrina Bazire· Investment Director
Sébastien Neiss· Director
Serge Prosman· Senior Advisor Belgium
Solenn Riffaud· Accounting Manager
Souhaila Tnifoui· Financial Controller
Stéphane Bergez· Partner, Head of Andera Actoin
Valentin Froment· Middle Officer
Vanessa Bonvalot· Executive Assistantin
Vanessa Favier-Klak· Chief Operating Officer
Vanessa Valluet· Team Assistant
Verane Wierucki· Investment Director
Victor Cabaud· Senior Investment Managerin
Vincent Bazzocchi· Partnerin𝕏
Vincent Croci· Investment Directorin
Wesley Peang· Senior Financial Controller
Yanis Feraoun· Investment Managerin

What they invest in

from 231 of 303 portfolio companies

Healthtech ×56Enterprise Software ×53Biotech ×47Medical Devices ×42Advanced Manufacturing ×38SaaS ×28Cleantech ×25Fintech ×21

HQs:France×133United States×21Belgium×7Germany×7Italy×5Switzerland×2

Who they back

founder profiles across 39 portfolio companies
54%
solo founders
21 of 39 mapped founding teams
29%
repeat founders
of 35 founders with career history
~3.5 yrs
old at investment
median across 16 dated deals

Founding team size:solo founder×212 founders×113 founders×24+ founders×5

Where their founders studiedfrom 30 founders with education data

Heidelberg University ×2Massachusetts Institute of Technology ×2Télécom Paris ×2Université catholique de Louvain ×2Université Claude Bernard Lyon 1 ×2Utrecht University ×2

What their founders studiedfrom 31 founders with field-of-study data

Life Sciences ×9Business & Management ×5Computer Science ×4Medicine ×4Chemistry ×3Economics ×3Finance & Accounting ×3Engineering ×2

Where their founders worked beforefrom 35 founders with career history

Google ×4Ecole Polytechnique ×2Owkin ×2UMC Utrecht ×2

12 founders hold a PhD · 4 hold an MBA (of 35 with degree data)

Investments · 303 tracked

founders shown can be your intro path

By year:2026 · 12025 · 62024 · 62023 · 102022 · 82021 · 22019 · 22018 · 72017 · 12015 · 144 dated

Avalyn Pharma Incavalynpharma.cominNASDAQ: AVLN

Avalyn Pharma develops inhaled therapies for pulmonary fibrosis, using a nebulization approach that delivers treatment directly to the lungs to reduce the tolerability problems of existing oral therapies.

BiotechHealthtech

Lyn Baranowski(CEO)in

Co-investorsCatalio Capital Management, LPF-Prime CapitalInVivium CapitalNorwest Venture PartnersPivotal Life SciencesRiverVest Venture Partners+9 more

Boston Scientificbostonscientific.cominNYSE: BSXAcquired

Boston Scientific supports external researcher-initiated studies through its Investigator Sponsored Research program, which funds independent investigations addressing disease understanding and treatment gaps of interest to the medical community.

HealthtechMedical Devices

John Abele(Founder)inPeter Nicholas(Founder)Lance BatesinJonathan R. Monson(Executive Vice President and Chief Financial Officer)Miriam O'Sullivan(Senior Vice President, Chief Human Resources Officer)inMichael F. Mahoney(Chairman of the Board, President and Chief Executive Officer)

Co-investorsCatalyst Health VenturesCouncilExcelestar VenturesGood Growth CapitalKleiner PerkinsLongitude Capital+8 more

Kestra Medical Technologieskestramedical.cominNASDAQ: KMTS

Kestra Medical Technologies develops wearable medical devices and digital healthcare solutions designed for collaborative care between providers and patients.

Digital HealthHardwareHealthtechMedical Devices

Brian Webster(President, Chief Executive Officer, and Director)inTraci S. Umberger(General Counsel, Chief Administrative Officer, and Director)inVaseem Mahboob(Chief Financial Officer)inAl Ford(Chief Commercial Officer)inTimothy Moran(Chief Business Officer)

Co-investorsBain Capital Life SciencesLongitude CapitalStar51 CapitalBain Capital

Mineralys Therapeuticsmineralystx.comin𝕏NASDAQ: MLYSSeries B · Jun 2022 · $120M

Mineralys Therapeutics is a clinical-stage pharmaceutical company developing lorundrostat, a treatment targeting dysregulated aldosterone.

BiotechHealthtechRadnor, US

Eric Warren(Chief Commercial Officer)inAlex Gold(Chief Medical Officer)inAdam Levy(Executive Officer)Alexander Asam(Director)

BoardBrian Taylor Slingsby(Founder & former CEO / Board Director)Olivier Litzka(Director)in

Co-investorsHBM Healthcare InvestmentsHBM PartnersSamsara BioCapitalSR One Capital ManagementYsios CapitalAdams Street Partners+3 more

CDS Groupcdsgroupe.com✓ verified

CDS Groupe (part of S4BT – Solutions for Business Travel) builds hotel booking and payment solutions for corporate business travel, serving companies and travel management agencies (TMCs).

B2B MarketplacesFintechTravel & HospitalityParis, FR

Ziad Minkara(Founder)

Crescendo Biologicscrescendobiologics.comin𝕏Jul 2023 · $32M✓ verified

Crescendo Biologics develops novel immune cell-enhancing therapeutics for immuno-oncology using its patent-protected Humabody VH platform, a fully human domain technology clinically validated in oncology and immunology.

BiotechHealthtechMedical Devices

Co-investorsQuan CapitalSofinnova PartnersAstellas Venture Management LLCEMBL VenturesFuture Planet CapitalAvlar BioVentures+3 more

eleveneleven-strategy.com✓ verified

A consulting firm that advises senior leaders on technology strategy and digital transformation, working primarily with large French enterprises and private equity funds to design and implement initiatives from strategy through execution.

AI & Machine LearningData & InfrastructureEnterprise SoftwareParis, FR

Co-investorsIsaiISAI Gestion

Eleven Strategyeleven-strategy.fr✓ verified

eleven strategy is a consulting firm that advises corporate leaders on designing, delivering, and scaling strategies through technological change, with a focus on the AI era.

AI & Machine LearningEnterprise Software

Bertrand S.(Founder)in

Enyo Pharmaenyopharma.comin𝕏Series B · Jun 2018 · $47M✓ verified

Enyo Pharma is a biotechnology company focused on drug development in the life sciences and therapeutics field.

BiotechHealthtechMedical DevicesLyon, FR

Jacky Vonderscher(Co-founder & CEO)inLaurène Meyniel-Schicklin(Founder, Head of Bioinformatics)inBenoît de Chassey(Founder, Head of Drug Discovery Platform)inPatrice André(Founder, Medical Advisor)inVincent Lotteau(Founder, Advisor)Jean-Jacques Garaud(Co-founder)in

Co-investorsOrbiMedSofinnova PartnersBpifrance

Highlife Medicalhighlifemedical.comin✓ verified

HighLife develops a transcatheter mitral valve replacement (TMVR/TSMVR) technology for patients with moderate to severe mitral regurgitation, implanted in a beating heart while preserving the native valve structure.

BiotechHealthtechMedical DevicesParis, FR

Georg Börtlein(Founder)inMalek Nasr(Founder)inRüdiger Lange(Founder (Heart Surgeon))Nicolo Piazza(Founder (Interventional Cardiologist))Stefan Pilz(CEO)inStephen Brecker(Chief Medical Officer)in

Co-investorsSofinnova PartnersCapricorn Venture PartnersUS Venture PartnersVI Partners

Kyothermkyotherm.cominFeb 2022 · $50M✓ verified

Kyotherm is an investment company that finances decarbonized heat and energy efficiency projects serving industrial, commercial, and public sector actors in Europe and North America.

CleantechClimate TechEnergy

Co-investorsInfraVia Capital PartnersStarquest CapitalBpifrance

Medical Micro Instrumentsmmimicro.comin𝕏Feb 2024✓ verified

MMI develops miniaturized robotic surgical instruments and platforms to enable surgeons to perform complex microsurgery and supermicrosurgery on delicate anatomical structures with greater precision.

HealthtechMedical DevicesRoboticsJacksonville, US

Mark Toland(Executive Officer, Director)inAndrew Cleeland(Director)Justin Lynch(Director)inTheresa Jean Cameron(Director)Caleb Moore(Executive Officer)Augusto Vianna Castello(Director)

Co-investorsBioStar CapitalDeerfield Management CompanyFidelity InvestmentsRA CapitalCorewell Health VenturesFountain Healthcare Partners

Nouscomnouscom.comSeries C · Nov 2023 · $73M✓ verified

Nouscom is a biotech company whose investors page lists its venture capital backers.

BiotechHealthtech

Riccardo Cortese(Co-Founder)Marina Udier(Chief Executive Officer and Board Director)Elisa Scarselli(Chief Scientific Officer and Co-Founder)Alfredo Nicosia(Co-founder)Antonella Folgori(Co-founder)Stefano Colloca(Co-founder)

Co-investors5AM VenturesAngelini VenturesRevelation PartnersXGEN VentureBpifranceEQT Life Sciences+6 more

Scirhomscirhom.cominSeries A · Jul 2024 · $68M✓ verified

SciRhom is a biotech company developing first-in-class humanized antibodies against iRhom2, which regulates the enzyme TACE/ADAM17 to block pro-inflammatory signaling pathways.

BiotechDeep TechHealthtechMartinsried, DE

Dr. Jens Ruhe(Co-founder, Managing Director & Chief Operating Officer)Dr. Matthias Schneider(Co-founder & Chief Scientific Officer)Dr. Jan Poth(Managing Director, Chief Executive Officer)Dr. Jürgen Reeß(Chief Medical Officer)

Co-investorsHadean VenturesKurma PartnersBayern KapitalHTGFMIG Capital AG

T-Knifet-knife.cominSeed · Aug 2021 · $9M✓ verified

T-knife Therapeutics is a biopharmaceutical company developing T cell therapies to treat cancer, with an initial focus on solid tumors.

BiotechHealthtechBerlin, DE

Elisa Kieback(Co-founder & Chief Technology Officer)inThomas Blankenstein(Scientific Founder)Thomas Soloway(Chief Executive Officer)Camille Landis(Chief Business Officer / Chief Financial Officer)inPeggy Sotiropoulou(Chief Scientific Officer)in

Co-investorsVersant VenturesEQT Life SciencesRA CapitalSixty Degree CapitalFidelity Investments

Tubulis GmbHtubulis.comin𝕏Series B · May 2022 · $63M✓ verifiedacquired by Gilead Sciences

Tubulis develops antibody-drug conjugates (ADCs) for cancer treatment, using proprietary conjugation platform technologies to create tumor-targeting therapeutics.

BiotechDeep TechMedical DevicesPlanegg-Martinsried, DE

Dominik Schumacher(Co-founder & CEO)inJonas Helma-Smets(Co-founder & Chief Scientific Officer)Christian Hackenberger(Scientific Co-founder)

Co-investorsBioMedPartnersEQT Life SciencesNexTech VenturesAscenta CapitalBayern Kapitalcoparion+8 more

2CGroup2c.groupin

2CGroup is a one-stop shop for entrepreneurs, giving startups and scale-ups access to experts across five areas: finance, marketing, innovation financing, human resources, and ESG.

Enterprise SoftwareFuture of WorkHR TechParis, FR

Abivaxabivax.comin𝕏

Abivax develops obefazimod, an orally administered small molecule drug candidate with a novel mechanism of action targeting microRNA biology to treat chronic inflammatory diseases including ulcerative colitis and Crohn's disease.

BiotechHealthtechMedical DevicesParis, FR

Marc de Garidel(CEO)in

Co-investorsClaret Capital PartnersMedicxiSamsara BioCapitalSofinnova PartnersTruffle CapitalMorgan Stanley

Abrisudabrisud.comin

Abrisud manufactures and sells pool enclosures, pool covers, and terrace structures including pergolas and spa shelters for residential customers across Europe.

Advanced ManufacturingConsumerl'Isle-Jourdain, FR

ACBacb.bein𝕏

ACB manufactures rigid, flex-rigid, and flexible printed circuit boards with advanced capabilities including up to 50 layers, specialized materials, and precision testing for industrial and electronics applications.

Advanced ManufacturingDeep TechHardwareDendermonde, BE

Ace Créditacecredit.fr

Ace Crédit is a French mortgage brokerage that helps individuals obtain real estate financing for primary or secondary residences, rental investments, and loan renegotiation.

FintechPropTech

Adcytherixadcytherix.comSeries A · Oct 2025 · $120M

Adcytherix is a clinical-stage biopharmaceutical company developing next-generation antibody-drug conjugates (ADCs) that use approved cancer drugs as payloads combined with optimized conjugation design to overcome resistance in precision oncology.

BiotechHealthtechMedical Devices

Jack Elands(Founder & CEO)inXavier Preville(Co-founder, VP & Head of Research & Preclinical Development)inJan H.M. Schellens(Chief Medical Officer)inThierry Menguy(VP & Head of CMC Operations)inJaime Arango(Chief Financial Officer)inPaul Jackson(Chief Operating Officer)in

Co-investorsaMoonRA CapitalBpifranceAngelini VenturesKurma PartnersPontifax Venture Capital+1 more

Adler Orthoadlerortho.cominOct 2025

Adler Ortho designs, manufactures, and markets joint prostheses and medical devices for the orthopaedic market.

Advanced ManufacturingHardwareHealthtechMedical DevicesCormano, IT

ADX Groupeadx-groupe.comin𝕏

ADX Groupe is an engineering and consulting firm that provides diagnostic and technical studies for existing buildings, industrial facilities, and infrastructure across sectors including real estate, construction, and environmental assessment.

CleantechConstruction TechPropTechUnknown (France implied but not stated), FR

Agomab Therapeuticsagomab.comin

Agomab is a clinical-stage biopharmaceutical company developing disease-modifying therapies for fibro-inflammatory and fibrotic diseases with high unmet medical need.

BiotechHealthtechMedical DevicesAntwerp, BE

Tim Knotnerus(Chief Executive Officer)in

Co-investorsEQT Life SciencesAdBio partnersAsabys PartnersCanaan PartnersPontifax Venture CapitalV-Bio Ventures+1 more

Alexion Pharmaceuticalsalexion.comin𝕏

Alexion is a biopharmaceutical company focused on research and development of treatments for rare diseases, serving rare disease patients and their families worldwide.

BiotechHealthtechBoston, US

Co-investorsConnecticut InnovationsvenBio Partners

Allecra Therapeutics GmbHallecra.com

Antibiotic developer, maker of cefepime/enmetazobactam (EXBLIFEP).

Co-investorsBioMedPartnersDelos CapitalEMBL VenturesXeraya CapitalForbion

Alouettealouette.fr𝕏

Alouette is a French regional radio station broadcasting music, news, and entertainment programming, with local content across western France (including Vendée, Charente, Loire-Atlantique, and other departments).

Media & Entertainment

Antoine V(Founder)in

Altaviaaltavia-group.comin𝕏

Kazaar is a marketing operations platform that automates campaign workflows, briefs, approvals, and production tasks for marketing and procurement teams.

AI & Machine LearningEnterprise SoftwareMarketing TechRetail TechSaaSSaint-Ouen, FR

Raphaël Palti(Chairman and Founder)in

Alveus Therapeuticsalveustx.cominDec 2025 · $197M

Alveus Therapeutics develops next-generation metabolic and obesity therapies, including its lead asset ALV-100 (in Phase 2) and a preclinical amylin pipeline of peptides, oral small molecules, and novel formats aimed at sustainable weight loss with better tolerability.

BiotechHealthtechLongevityPhiladelphia, US

Raj Kannan(Executive Officer, Director)

BoardClaudio Nessi(Director)inIvan Gergel(Director)inJan Van de Bossche(Director)inGarrett Ingram(Director)Gregory Parekh(Director)

Co-investorsAvego BioScience CapitalGlobal BioAccess FundJeito CapitalNew Rhein Healthcare Investors, LLCSeroba Life SciencesAgent Capital+2 more

AM Pharmaam-pharma.comin

AM-Pharma develops ilofotase alfa, a recombinant alkaline phosphatase enzyme therapy, and is studying it as a treatment for adults with hypophosphatasia (HPP), a rare inherited metabolic bone disease.

BiotechHealthtech

Co-investorsKurma PartnersYsios CapitalForbion

Amolyt Pharmaamolytpharma.comSeries C · Jan 2023 · $140M

Developing therapeutic peptides targeting rare endocrine diseases (past investment).

Co-investorsATEM Capital FundCTI Life Sciences Fund L.P.EQT Life SciencesKurma PartnersOctalfaSofinnova Partners+4 more

Anacorin𝕏Acquired

Pfizer discovers, develops, manufactures, and distributes pharmaceutical medicines and vaccines across therapeutic areas including oncology, cardiology, immunology, and infectious diseases.

BiotechHealthtechMedical DevicesNew York, US

Charles Pfizer

Co-investorsAisling CapitalRho Capital PartnersRho VenturesRiverVest Venture PartnersVenrockNew Enterprise Associates (NEA)

Anetaaneta.companyMay 2023

Aneta operates an email-based AI research service that runs 15 specialized agents across academic, market, technical, and legal sources for days to produce long, citation-backed research reports.

AI & Machine LearningEnterprise SoftwareSaaS

Co-investorsPebblebedBGVForbionFountain Healthcare PartnersHTGFPMV+2 more

Antemetaantemeta.frin𝕏

AntemetA provides enterprise software implementation and managed services, specializing in SAP deployments and business applications across cloud and on-premises environments.

Advanced ManufacturingCloud ComputingEnterprise Software

Arcaplanet (Fortesan)arcaplanet.it𝕏

Online retailer specializing in pet supplies and products for dogs and cats, including food and health solutions.

ConsumerE-commerceRetail Tech

ARCHIVECOarchiveco.fr𝕏

Xelians provides document management and digitization services, including data structuring, archiving, dematerialization, and business process automation for organizations across all sectors.

Data & InfrastructureEnterprise Software

Artios Pharmaartios.comin𝕏Series B · Aug 2018 · $83M

Artios develops DNA damage response (DDR)-based medicines targeting patients with high unmet need cancers.

BiotechHealthtechMedical Devices

Co-investorsDementia Discovery FundM VenturesNovartis Venture FundPfizer Venture InvestmentsRA CapitalSofinnova Partners+6 more

Arvelle Therapeuticsangelinipharma.chinFeb 2019 · $180M

Angelini Pharma Switzerland is the Swiss arm of a pharmaceutical company focused on brain health and epilepsy, offering prescription treatments for patients and healthcare professionals.

BiotechConsumerHealthtechZug, CH

Co-investorsF-Prime CapitalH.I.G. CapitalH.I.G. HealthBridge PartnersBRV Capital ManagementEQT Life SciencesH.I.G. BioHealth Partners

Atlandatland.fr

ATLAND is a publicly listed real estate group that designs and manages real estate investment products across the property value chain.

FintechPropTech

Atlantic Therapeuticscalderamedical.comJan 2019

Caldera Medical develops surgical solutions for women's health conditions including stress urinary incontinence, pelvic organ prolapse, polyps, and fibroids.

FemTechHealthtechMedical Devices

Co-investorsBorski FundSeroba Life SciencesAtlantic Bridge VenturesBek VenturesEarlybird Venture CapitalEQT Life Sciences

Au Forum Du Bâtimentauforumdubatiment.frin

Au Forum du Bâtiment is an independent distribution network selling building hardware, locksmithing, industrial supplies and tools, plumbing, sanitary, heating and air conditioning products to construction professionals.

Advanced ManufacturingB2B MarketplacesConstruction TechE-commerce

Co-investorsCrédit Mutuel Equity

Aurisaurisgestion.com

Auris Gestion is an independent asset management firm offering asset allocation and wealth management services across three activities serving independent financial advisors and family offices, institutional clients, and private clients.

Fintech

Co-investorsMithril Capital ManagementCoatue ManagementLux CapitalViking Global Investors

Auxigaauxiga.comin

Auxiga provides inventory-backed guarantees and asset control services, helping businesses use their stock as collateral to finance growth.

Enterprise SoftwareFintech

Axonics Modulation Technologiesaxonics.comin

Boston Scientific develops medical devices and technologies used by healthcare professionals to treat patients across a range of conditions.

HealthtechMedical DevicesIrvine, US

Michael Williamson(Executive Officer)Dan L. Dearen(Executive Officer)inRaymond Cohen(Executive Officer, Director)in

BoardDarren Cai(Director)Raphael Wisniewski(Director)Erik Amble(Director)

Co-investorsAdvent Life SciencesLongitude CapitalGilde Healthcare

Aymingayming.comin

Ayming is a consulting firm that helps companies secure direct funding for R&D, innovation, and capital-intensive projects by matching projects with grants, loans, and other public and private financing instruments.

Enterprise SoftwareFintechHR TechLegalTechSaaSSector AgnosticLondon, GB

B2Skonecta.comin

Konecta is a global experience and customer engagement company that combines human expertise with AI technology to help businesses enhance customer relationships and employee engagement.

AI & Machine LearningEnterprise SoftwareImpact & Social GoodMarketing Tech

José María Pacheco(Founder & President)inMariano Castanos ZemboraininNourdine Bihmane(Chief Executive Officer)in

Bacacierbacacier.com

Bacacier manufactures and sells metal facade, roofing, and structural solutions for construction, including profiled cladding, sandwich panels, and thermal insulation systems.

Advanced ManufacturingConstruction TechE-commerceNew Materials

BEA Groupbeagroup.euin

BEA Group is an insurance brokerage and services group serving professional clients through specialized firms, covering areas such as medical liability for public and private institutions, public sector liability, SME insurance, construction, and claims management.

FintechInsurTech

Bioclinicbioclinic.fr

BioClinique operates a network of medical laboratories providing clinical testing services across the Île-de-France region in France.

Healthtech

Biogroup-LCDbiogroup.frin𝕏

Biogroup Fertilité operates a network of fertility and assisted reproduction centers providing in vitro fertilization, artificial insemination, and fertility preservation services to patients across multiple locations.

HealthtechMedical Devices

Co-investorsLa Caisse

Biolamgroupebiolam.com

Groupe Biolam operates a network of medical biology laboratories that provide diagnostic analyses and support patients in their care pathway.

Digital HealthHealthtech

Bioptimusbioptimus.cominJan 2025

Bioptimus is an AI-first biotech company developing a universal AI foundation model that connects biology across scales, from molecules and cells to tissues and whole organisms, to support biomedical research and innovation.

AI & Machine LearningBiotechDigital HealthHealthtechParis, FR

Eric Durand(Founder)inFelipe Llinares-López(Co-founder & VP of AI)inRodolphe Jenatton(Founder)inZelda Mariet(Founder)inJean-Philippe Vert(Founder)inDavid Cahané(Co-founder & General Manager)

Co-investorsCathay InnovationFELIX CAPITALFrstHeadlineHeadline Growth Management, LLCHitachi Ventures+8 more

Bioventrixbioventrix.comin𝕏Series A · Apr 2023 · $49M

BioVentrix is a medical device company that develops less invasive therapies to treat heart failure by reconstructing the dilated left ventricle using myocardial micro-anchor implants.

BiotechHealthtechMedical DevicesMansfield, US

DAVID RICHMOND(Executive Officer, Director)inSTEVE CHARTIER(Executive Officer)inJAMES DILLON(Executive Officer, Director)ORI BEN-YEHUDA(Executive Officer)WILLIAM ABBOTT(Executive Officer)inMiller Ken(Executive Officer, Director)

CertiNergycertinergy.comin

Certinergy assists building professionals and property owners with energy efficiency projects through technical solutions and financial support, including energy savings certificates (CEE) in France.

CleantechConstruction TechEnergyFrance, FR

CESAcesa-groupe.comacquired by Ortec Group

CESA CFA is an agency of the Ortec Group specializing in electrical engineering and low-current (courants faibles) systems, including fire safety, communication networks, and security systems for building renovation and new construction.

Construction TechCybersecurityEnergyÉmerainville, FR

Cetalcetal.fr

CETAL provides industrial heating and heater optimization services for manufacturing sectors including petrochemicals, plastics, packaging, power generation, and food production.

Advanced ManufacturingCleantechClimate TechEnergyEnterprise Software

Chabéchabe.comin

Chabé provides chauffeur and bespoke transportation services for luxury clients, including Parisian luxury "Palace" hotels, and offers journey management for large-scale public and private events.

Mobility & TransportationTravel & HospitalityParis, FR

CHASE Pharmaceuticalschasepharmaceuticals.com

Irvine, CA based Alzheimer's drug company

BiotechWashington, US

Thomas N. Chase(Executive Officer, Director)Douglas Ingram(Executive Officer, Director)John M. Siebert(Executive Officer, Director)Kathleen Clarence-Smith(Executive Officer)

BoardNayan Greg Parekh(Director)John M. Reher(Director)in

Co-investorsNew Rhein Healthcare Investors, LLCBrain Trust Accelerator Fund

Complixcomplix.com

Complix develops therapeutic biologics based on Alphabody technology targeting viral diseases, oncology, and autoimmune conditions.

AI & Machine LearningBiotechDeep TechMedical Devices

Co-investorsPMVVesalius Biocapital PartnersGimvOmnes Capital

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

A2IAADFAriceumAriceum TherapeuticsArtemysAutonomic TechnologiesAxellianceCellnovoChampeauCMPComplexaCorvidia TherapeuticsCovagen AGDocument StoreDP LogicielsDualyxEG 427Euro ProtectionExclusive GroupFaabFilaFlamingo TherapeuticsGAMAMABSGEOTECGroupe ERIGroupe FontanelGroupe GostoGroupe OrestHTIHVJHypérion DéveloppementIngenostrumInotremItesaKlaxcarKopramLa Vie SaineLagarrigueLegallaisMedDay PharmaceuticalsMMI

Browse all 303 investments with full details →

▶103 more tracked companies

NexiraNG TravelNoxxonNumansNyxoahOberthurOCEAOcéanOCTIMEOlaqinOncoEthixOneXilliumOpportunityOrbilityParvulus MedicalPassmanPatrimmofiPauwels ConsultingPegaOnePENNEL & FLIPOPhilia Medical EditionsPhilia Medical EditionsPhilogerisPlasseraud IPPlatinium GroupPM StudioPotel & ChabotPoxelPrenaxPrenaxProwebCEPusterla 1880QovoltisQualisteoREALEASERedSlimRenaud DistributionRésonance Imagerie GroupReViralRivermarkSagitta PharmaSanifitSanso LongchampSapiensSapore di MareSarawakScalianSenstronicSerenySunSerenySun InvestSergent MajorSFAMSFEIRSIRSASkill & YouSkysunSmileSnadecSodimeSOFT COMPANYSogetrelSolwareSoniVieSotraluSpartesSpengler GroupSphereaSpiro MedicalStar ServiceStats PerformStudiaSun CitySuperSonic ImagineSYCLEFSylpaSynacktivTargED BiopharmaceuticalsTBS GroupTecnikabelTelamonTelecom DesignTerr AThe Reefer GroupThomson Video NetworksTiepoloTimeOne GroupTobira TherapeuticsTournus EquipementTravelsoftTRiCares GmbH and SASTrillium TherapeuticsTurbocoatingTX CubeVerona PharmaVignalVignalVivoryonVolta CroissanceVoyageurs du MondeWatt & Co GroupWFCWFCIXelians

Exits · 12

4 IPOs · 8 acquisitions · showing 9

Avalyn Pharma IncNASDAQ: AVLNBoston ScientificNYSE: BSXKestra Medical TechnologiesNASDAQ: KMTSMineralys TherapeuticsNASDAQ: MLYSTubulis GmbHacq. by Gilead SciencesCESAacq. by Ortec GroupCovagen AGacq. by Johnson & JohnsonImcheckacq. by ClementiaLimmaTech Biologicsacq. by Lilly

Portfolio news

latest coverage across their companies

Public market activity · per SEC filings

what is this? ⓘ
Mineralys Therapeutics, Inc.SC 13G

Disclosed stake · filed Feb 2023

view filing ↗
SC 13G/A filingSC 13G/A

Disclosed stake · filed Oct 2022

view filing ↗
SC 13G/A filingSC 13G/A

Disclosed stake · filed Feb 2021

view filing ↗
SC 13D/A filingSC 13D/A

Disclosed stake · filed Feb 2021

view filing ↗
SC 13D/A filingSC 13D/A

Disclosed stake · filed May 2020

view filing ↗
SC 13G/A filingSC 13G/A

Disclosed stake · filed Feb 2020

view filing ↗
SC 13D/A filingSC 13D/A

Disclosed stake · filed Jan 2020

view filing ↗
SC 13D/A filingSC 13D/A

Disclosed stake · filed Dec 2019

view filing ↗
SC 13G filingSC 13G

Disclosed stake · filed Feb 2019

view filing ↗
SC 13G/A filingSC 13G/A

Disclosed stake · filed Feb 2019

view filing ↗
SC 13D filingSC 13D

Disclosed stake · filed Dec 2018

view filing ↗

4 insider ownership filings (Forms 3/4/5)

Files 13F institutional holdings reports · latest Oct 2026

From the firm's own SEC EDGAR filings — stakes and insider roles in public companies, typically portfolio companies after an IPO. Not a portfolio list published by the firm.

Frequently asked questions

How many investments has Andera Partners made?
Andera Partners has 303 tracked investments, 12 of which have exited, including 8 dated in the last 24 months.
What stage does Andera Partners invest at?
Andera Partners invests at the Seed, Series A, Series B, Series C, Growth stages.
What sectors does Andera Partners focus on?
Andera Partners focuses on Advanced Manufacturing, Biotech, Cleantech, Climate Tech, Data & Infrastructure, Energy, Healthtech, Mobility & Transportation, Sector Agnostic.
Where is Andera Partners located?
Andera Partners is headquartered in Paris, FR.
Does Andera Partners lead rounds?
Andera Partners has led 5 of the 23 rounds where its role is on record.
Who does Andera Partners co-invest with?
Andera Partners most often shares deals with Sofinnova Partners, New Enterprise Associates (NEA), Kurma Partners, among 170 tracked co-investors.
What size deals does Andera Partners back?
Across 26 deals with disclosed amounts, Andera Partners has joined rounds of $9M – $240M (median $61.5M).

Media · Podcasts & interviews

featuring the team

L'observatoire du CARVE-OUT 2023 - Mayeul Caron, Partner, Andera Partners

4Change · Mayeul Caron

David Solomon (Pharnext) & Olivier Litzka (Andera Partners) : Le journal des Biotechs

Boursorama · Olivier Litzka

Images

Andera Partners photoAndera Partners photoAndera Partners photo

Co-investors · 24

EQT Life Sciences

EQT Life Sciences (formerly LSP) is one of Europe's largest and most experienced life sciences investors, backing companies developing therapeutics, medical devices, diagnostics and healthtech globally.

$11M – $66M
RA Capital

RA Capital Management is a healthcare and planetary health investment firm that founds, funds, and scales companies using scientific diligence, multi-stage capital, and hands-on operational support.

Kurma Partners

Kurma Partners is a European healthcare-focused investment firm that co-founds and finances biotech and healthcare companies, working closely with research centers to translate scientific discoveries into high-tech companies.

$162K – $10.8M
OrbiMed

OrbiMed is a healthcare-focused investment firm providing tailored financing solutions and global resources to build world-class healthcare companies across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services.

$1M – $75M
Ysios Capital

Ysios Capital is a life sciences venture investor that finances innovative biotech companies developing novel therapies for high unmet medical needs, primarily across Europe and the United States.

$5.4M – $21.6M
Pfizer Venture Investments

Pfizer Venture Investments is a strategic venture fund that doesn't require product or technology rights as a condition of investing, giving founders independence while still aiming for future collaboration with Pfizer, and its team blends venture investing with business development and drug discovery expertise to back frontier scientific bets—such as neuroscience, in-vivo cell engineering, dark-genome target discovery, and the blockchain-based longevity accelerator VitaDAO—that many biotech investors avoid. The fund also runs an active China strategy through a locally based venture vehicle and direct investments like OTR Therapeutics, and it has become a channel for strategic deals, with portfolio companies acquired by AbbVie, Ipsen, and Gilead/Kite.

$5M – $20M
Forbion

Forbion is a global venture capital firm focused on advancing biotech innovations and other sustainable solutions aimed at improving human and planetary health.

Deerfield Management Company

Deerfield Management Company is a healthcare-focused investment firm, founded in 1994, that advances healthcare through investment, intelligence, and philanthropy.

Both backed · 3
Novartis Venture Fund

Novartis Venture Fund is the corporate venture arm investing in life science companies, backing innovative drugs and treatments across various stages of growth.

Both backed · 3
$5M – $25M
Pontifax Venture Capital

Pontifax is a venture capital firm focused on life sciences and healthcare technologies, investing across all development stages from early-stage startups to clinical-stage growth companies.

Pureos Bioventures

Pureos Bioventures is a venture capital firm that invests in private, innovative drug development companies, with a focus on next-generation biological drugs and drug formats to treat severe diseases.

Both backed · 3
AdcytherixImcheckAriceum Therapeutics
Venrock

Venrock is a venture capital firm investing across technology and healthcare, backing companies in fintech, developer infrastructure, life sciences, therapeutics, semiconductors, and consumer products.

Both backed · 2
$500K – $10M
▶12 more co-investors

Earlybird Venture CapitalVersant VenturesAtlas Venture5AM VenturesBioGeneration VenturesFrazier Healthcare PartnersInkefApollo Health VenturesBain Capital VenturesARCH Venture PartnersXtripe AngelsThird Rock Ventures

Firms observed investing alongside Andera Partners, from public investor directories. Shared companies are the overlap with Andera Partners's recorded portfolio.

Similar investors

Featured in lists